Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Pre-Mkt 01-29 06:29:13 EST

496.54

-3.85

-0.77%

High506.40	Low492.00	Vol180.95K
Open504.36	D1 Closing500.39	Amplitude2.88%
Mkt Cap11.28B	Tradable Cap5.46B	Total Shares22.71M
T/O89.95M	T/O Rate1.64%	Tradable Shares11.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":496.54,"timestamp":1769634000000,"preClose":500.39,"halted":0,"volume":180945,"delay":0,"changeRate":-0.00769399868102873,"floatShares":11000087,"shares":22711420,"eps":-13.035484,"marketStatus":"Pre-Mkt","change":-3.85,"latestTime":"01-29 06:29:13 EST","open":504.36,"high":506.395,"low":492,"amount":89945940.59199,"amplitude":0.028768,"askPrice":505.5,"askSize":29,"bidPrice":490,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-13.035484,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769697000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":496.54,"postHourTrading":{"tag":"盘后","latestPrice":496.1,"preClose":496.54,"latestTime":"16:15 EST","volume":927,"amount":460226.24,"timestamp":1769634914642,"change":-0.44,"changeRate":-0.000886,"amplitude":0.000886},"volumeRatio":0.5797201741398166,"impliedVol":0.5045,"impliedVolPercentile":0.14},"requestUrl":"/m/hq/s/MDGL/tweets","defaultTab":"tweets","newsList":[{"id":"2607779964","title":"Rezdiffra Sales Milestone and Pfizer DGAT-2 Deal Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607779964","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607779964?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:38","pubTimestamp":1769643481,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals recently reported that its liver disease drug Rezdiffra has reached over US$1.00 billion in annualized sales, while also signing an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage DGAT-2 inhibitor to expand its MASH treatment pipeline.\nThis combination of rapid commercial uptake for Rezdiffra and external pipeline expansion with Pfizer highlights how Madrigal is trying to build a broader franchise in liver disease treatments.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/rezdiffra-sales-milestone-and-pfizer-dgat-2-deal-might-chang","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/rezdiffra-sales-milestone-and-pfizer-dgat-2-deal-might-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999003800.SGD","IE00BBT3K403.USD","LU0289739699.SGD","LU0321505868.SGD","IE0002270589.USD","LU1883839398.USD","LU0306806265.USD","BK4568","LU0058720904.USD","LU0306807586.USD","LU0225771236.USD","SG9999013999.USD","SG9999001176.USD","SG9999002224.SGD","BK4007","LU0321505439.SGD","LU1023059063.AUD","IE000M9KFDE8.USD","LU0225284248.USD","LU0985481810.HKD","BK4550","LU0234572021.USD","LU0456855351.SGD","LU1066053197.SGD","MDGL","LU0122379950.USD","LU1066051498.USD","IE00B19Z3581.USD","SG9999002232.USD","BK4139","BK4534","BK4592","LU1057294990.SGD","SGXZ57979304.SGD","BK4581","BK4533","BK4585","SG9999001176.SGD","IE00BLSP4452.SGD","LU1894683264.USD","LU0170899867.USD","BK4588","LU1894683348.USD","BK4599","IE00B19Z3B42.SGD","SG9999011175.SGD","IE00BLSP4239.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2606748778","title":"Biotech Inventiva's 50% surge shows investor optimism over liver disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2606748778","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606748778?lang=en_us&edition=fundamental","pubTime":"2026-01-28 23:36","pubTimestamp":1769614577,"startTime":"0","endTime":"0","summary":"Biotech Inventiva's 50% surge shows investor optimism over liver disease drugInventiva shares up 50% in JanuaryOptimism builds around its MASH drugBig Pharma signal strategic interestA lot riding out Phase 3 outcomeEvaluating funding options, CEO tells ReutersBy Danilo Masoni","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL8N3YS1TD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905037.USD","LU0203345920.USD","LU0321505439.SGD","LU1400636657.SGD","BK4585","LU1983299246.USD","LU0211331839.USD","ETNB","LU0306806265.USD","LU1202635105.USD","LU1309081286.SGD","BK4207","MDGL","LU1400636574.HKD","GSK.UK","BK5011","IE00B3T34201.USD","LU1481600234.SGD","LU0225771236.USD","LU0058720904.USD","LU1228905540.USD","LU0225284248.USD","IE00BWDBJ516.SGD","LU0971552830.HKD","LU0289739699.SGD","LU1645745479.HKD","LU1015430645.USD","BK4139","LU1487256676.USD","LU0575583348.USD","IE0034235071.USD","LU0306807586.USD","LU0321505868.SGD","LU0203347892.USD","LU1302929846.USD","MNSH","LU0161305163.EUR","LU1400636491.USD","LU0109981661.USD","LU1481599808.USD","LU0971552673.USD","LU1670756490.USD","LU0985481810.HKD","LU0545562505.USD","IE00BQJZX424.USD","LU1046248800.SGD","LU1098665638.USD","LU1064927863.SGD","LU1035777561.USD","BK4588"],"gpt_icon":0},{"id":"2606710601","title":"Madrigal Pharmaceuticals Initiated at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606710601","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606710601?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:52","pubTimestamp":1769611920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 09:52 ET (14:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"gpt_icon":0},{"id":"2606975341","title":"Madrigal Pharmaceuticals initiated with an Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606975341","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606975341?lang=en_us&edition=fundamental","pubTime":"2026-01-28 05:31","pubTimestamp":1769549488,"startTime":"0","endTime":"0","summary":"Barclays initiated coverage of Madrigal Pharmaceuticals (MDGL) with an Overweight rating and $964 price target Barclays initiated coverage of 12 bi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-initiated-with-an-overweight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-initiated-with-an-overweight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2606780045","title":"Madrigal Pharmaceuticals Lobbying And Insider Sales Put Valuation In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2606780045","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606780045?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:31","pubTimestamp":1769513500,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (NasdaqGS:MDGL) has recently reported increased lobbying activity tied to US drug pricing policy, including CMMI and Most Favored Nation frameworks.\nOver the same period, company executives have carried out meaningful insider share sales that may draw attention from investors tracking management activity.\nThese disclosures arrive with Madrigal's share price at $499.17 and highlight fresh non financial developments that could shape sentiment around the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-lobbying-and-insider-sales-put-valu","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-lobbying-and-insider-sales-put-valu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2606547972","title":"Can Trump and Big Pharma Get the World to Pay More for Drugs? -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2606547972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606547972?lang=en_us&edition=fundamental","pubTime":"2026-01-25 18:30","pubTimestamp":1769337000,"startTime":"0","endTime":"0","summary":"Americans pay about three times what other wealthy nations do for branded prescription drugs. For years, policymakers have tried to fix this by cutting U.S. drug prices directly. President Trump has pushed a different idea: make foreign countries pay more so Americans can pay less.For Big Pharma, there is potential upside. But it is easier said than done.Last year, after threatening the industry with crushing tariffs, Trump secured several commitments. The most important one: Drugmakers agreed to charge the U.S. no more than what other wealthy countries pay for newly launched medicines, as part of a policy known as \"most favored nation,\" or MFN.Now, Trump's recent threats to place tariffs on European countries over Greenland could make them less inclined to oblige the U.S. on drug prices. But one thing to keep in mind is that in pharma, many of the companies demanding h","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","LU2462157665.USD","LU0320765992.SGD","RHHBY","LU0109394709.USD","BK4585","LU0889565916.HKD","LU2236285917.USD","MDGL","AZN","LU2456880835.USD","BK4139","BK4007","BK4588","BK4568","LU2417539215.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2605244300","title":"BRIEF-Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605244300","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605244300?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:11","pubTimestamp":1769123514,"startTime":"0","endTime":"0","summary":"BRIEF-Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)Jan 22 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:MADRIGAL PHARMACEUTICALS ANNOUNCES GRANT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA2K7NYY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MDGL","BK4585","BK4139"],"gpt_icon":0},{"id":"2605441815","title":"Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer License For Ervogastat In MASH Therapy Combinations","url":"https://stock-news.laohu8.com/highlight/detail?id=2605441815","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605441815?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:36","pubTimestamp":1769121406,"startTime":"0","endTime":"0","summary":"Madrigal’s new Pfizer license puts MASH combinations in focus\nMadrigal Pharmaceuticals (MDGL) has moved into the spotlight after signing an exclusive global license agreement with Pfizer for ervogastat, a clinical stage DGAT 2 inhibitor aimed at MASH combination therapies.\nThe deal ties Madrigal’s existing MASH franchise to a potential companion drug that targets triglyceride assembly and liver fat. This pairing is one investors may watch closely as the company outlines its plans at the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-valuation-after-new-pfizer-lic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-valuation-after-new-pfizer-lic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999013999.USD","MDGL","LU0234572021.USD","SG9999003800.SGD","LU0170899867.USD","BK4585","IE00BLSP4452.SGD","LU1894683264.USD","SG9999001176.SGD","IE00BLSP4239.USD","LU0225771236.USD","LU1066051498.USD","LU1066053197.SGD","BK4581","LU1057294990.SGD","IE00B19Z3581.USD","LU0289739699.SGD","BK4592","IE000M9KFDE8.USD","LU0058720904.USD","BK4568","BK4533","SGXZ57979304.SGD","BK4007","IE00BBT3K403.USD","LU0321505439.SGD","LU1883839398.USD","SG9999002232.USD","LU0306806265.USD","BK4139","LU0225284248.USD","LU0306807586.USD","LU0985481810.HKD","BK4599","LU0456855351.SGD","BK4550","SG9999001176.USD","IE0002270589.USD","LU0122379950.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","SG9999002224.SGD","LU1023059063.AUD","LU0868494617.USD","LU1894683348.USD","LU0321505868.SGD","BK4588","BK4534"],"gpt_icon":0},{"id":"2605027438","title":"Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605027438","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605027438?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:05","pubTimestamp":1769029500,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., Jan.  21, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/21/3223236/0/en/Madrigal-Pharmaceuticals-Announces-Grant-of-Inducement-Award-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","MDGL"],"gpt_icon":0},{"id":"2605171252","title":"U.S. RESEARCH ROUNDUP-Datadog, IBM, Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2605171252","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605171252?lang=en_us&edition=fundamental","pubTime":"2026-01-21 16:17","pubTimestamp":1768983435,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Datadog, IBM, NetflixJan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Datadog, IBM and Netfl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"cf2321d09511694ceb970f964de69f94","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM0N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SFM","Q","DD","HWC","AZN.UK","DAR","EE","KLAC","LRCX","PNFP","TCBI","HSY","AME","FRPT","DDOG","MMM","LC","03165","WTFC","CPB","LU2237957902.USD","WEX","AU","USB","MNSH","KHC","KWR","TSN","MDGL","NFLX","HSBA.UK","IBM","ZION","MDLZ","BG","POST","TKO","CPAY","XEL","RAPT","BRBR","FITB","BOKF","FISV","ALB","CTVA","IBKR","FRMI"],"gpt_icon":1},{"id":"2605129987","title":"Top Madrigal Pharmaceuticals Insiders Quietly Cash In On Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605129987","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605129987?lang=en_us&edition=fundamental","pubTime":"2026-01-21 10:01","pubTimestamp":1768960892,"startTime":"0","endTime":"0","summary":"New insider activity at Madrigal Pharmaceuticals ( ($MDGL) ) has taken place on January 20, 2026. Recent insider activity at Madrigal Pharmaceutica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-madrigal-pharmaceuticals-insiders-quietly-cash-in-on-shares-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-madrigal-pharmaceuticals-insiders-quietly-cash-in-on-shares-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","MDGL"],"gpt_icon":0},{"id":"2605567142","title":"Madrigal Pharmaceuticals Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Rita Thakkar","url":"https://stock-news.laohu8.com/highlight/detail?id=2605567142","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605567142?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:22","pubTimestamp":1768947759,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Rita Thakkar as the beneficial owner, serving in the role of Chief Accounting Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL9nzXrn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Madrigal Pharmaceuticals Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Rita Thakkar","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","MDGL","BK4585"],"gpt_icon":0},{"id":"2604198461","title":"Madrigal Pharmaceuticals Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2604198461","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604198461?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:59","pubTimestamp":1768917540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 20, 2026 08:59 ET (13:59 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"gpt_icon":0},{"id":"2604944781","title":"Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2604944781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604944781?lang=en_us&edition=fundamental","pubTime":"2026-01-20 18:55","pubTimestamp":1768906509,"startTime":"0","endTime":"0","summary":"Citizens raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $745 from $527 and keeps an Outperform rating on the shares. Rezdiffr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-raised-to-745-from-527-at-citizens-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-raised-to-745-from-527-at-citizens-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2603193799","title":"Assessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2603193799","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603193799?lang=en_us&edition=fundamental","pubTime":"2026-01-16 04:42","pubTimestamp":1768509760,"startTime":"0","endTime":"0","summary":"Madrigal’s new Pfizer partnership puts MASH combinations in focus\nMadrigal Pharmaceuticals (MDGL) just signed an exclusive global license agreement giving Pfizer rights to ervogastat, a clinical-stage oral DGAT-2 inhibitor. This agreement directly targets future combination approaches in metabolic liver disease.\nThe deal centers on DGAT-2’s role in triglyceride assembly and liver fat storage, an area closely linked to inflammation in MASH. Investors now have a new data point to watch as...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/assessing-madrigal-pharmaceuticals-mdgl-valuation-after-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/assessing-madrigal-pharmaceuticals-mdgl-valuation-after-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4550","MDGL","LU0289739699.SGD","LU1023059063.AUD","SG9999011175.SGD","BK4599","SG9999003800.SGD","IE00B19Z3B42.SGD","BK4581","BK4592","BK4585","IE0002270589.USD","LU0225771236.USD","LU0306806265.USD","LU0122379950.USD","LU1066051498.USD","LU0321505439.SGD","SG9999002232.USD","LU0306807586.USD","LU1894683348.USD","BK4534","BK4139","PFE","IE00BLSP4239.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","SG9999001176.SGD","LU0058720904.USD","LU0456855351.SGD","LU0321505868.SGD","LU1066053197.SGD","BK4588","LU0225284248.USD","BK4007","SG9999002224.SGD","LU1883839398.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU1057294990.SGD","BK4533","LU1894683264.USD","IE00BLSP4452.SGD","BK4568","LU0234572021.USD","LU0868494617.USD","LU0170899867.USD","LU0985481810.HKD","IE00B19Z3581.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"2603653849","title":"Director Paul A. Friedman Reports Disposal of Madrigal Pharmaceuticals Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653849","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603653849?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:43","pubTimestamp":1768340630,"startTime":"0","endTime":"0","summary":"Paul A. Friedman, Director at Madrigal Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL1lSX2Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","MDGL"],"gpt_icon":0},{"id":"2603658443","title":"Director Rebecca Taub Reports Disposal of Madrigal Pharmaceuticals Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603658443","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603658443?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:34","pubTimestamp":1768340090,"startTime":"0","endTime":"0","summary":"Rebecca Taub, Director of Madrigal Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL7SQSnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Rebecca Taub Reports Disposal of Madrigal Pharmaceuticals Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","MDGL","BK4139"],"gpt_icon":0},{"id":"2602591753","title":"U.S. RESEARCH ROUNDUP-American Express, Ameriprise Financial, Mastercard","url":"https://stock-news.laohu8.com/highlight/detail?id=2602591753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602591753?lang=en_us&edition=fundamental","pubTime":"2026-01-12 15:42","pubTimestamp":1768203746,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-American Express, Ameriprise Financial, MastercardJan 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, inc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL4N3YD0E7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNC","GL","AA","CRBG","LU2764263203.CNY","AFL","JXN","LU1119994496.HKD","LU2491050154.USD","AIR","MET","NMRA","COF","H","AMP","BFH","CCI","EQH","GPN","MDLN","FISV","OMF","MAR","DG","BA","AXP","OPRT","ALLY","JAZZ","LU1868837136.USD","AMT","CSGP","MDGL","NUE","CHH","HLT","LU1548497426.USD","LU0316494557.USD","STZ","CE","BK4585","INSM","AD","LU1718418525.SGD","PYPL","CNO","PARR","MCHP","MA","PSX"],"gpt_icon":1},{"id":"2602859899","title":"Madrigal Pharmaceuticals Inc : TD Cowen Raises Target Price to $644 From $554","url":"https://stock-news.laohu8.com/highlight/detail?id=2602859899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602859899?lang=en_us&edition=fundamental","pubTime":"2026-01-12 12:50","pubTimestamp":1768193416,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YA1DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2602552661","title":"Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602552661","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602552661?lang=en_us&edition=fundamental","pubTime":"2026-01-12 01:01","pubTimestamp":1768150860,"startTime":"0","endTime":"0","summary":"A wave of analyst downgrades, outlook resets and company-specific headlines pushed last week's biggest large-cap losers lower, led by First Solar, Roblox, and Madrigal.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/11/Little-Boy-Playing-Roblox-Game-On-A-Tabl.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/11/Little-Boy-Playing-Roblox-Game-On-A-Tabl.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/01/49831856/roblox-first-solar-and-league-enterprise-are-among-top-10-large-cap-losers-last-week-jan-5-jan-9-are-the-others-in-your-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/01/49831856/roblox-first-solar-and-league-enterprise-are-among-top-10-large-cap-losers-last-week-jan-5-jan-9-are-the-others-in-your-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["MDGL","SQQQ","LU2065171311.SGD","LU2290526834.HKD","LU0274383776.USD","IE00B894F039.SGD","LU0320765489.SGD","QID","NRG","LU2177674079.SGD","RBLX","TQQQ","FSLR","LU0345774391.USD","LU0130103400.USD","LU0823434740.USD","QLD","NVIW.SI","BK4079","USAW.SI","HDB","JCI","LU0130517989.USD","NQmain","LU0323239441.USD","LU2095319765.USD","PSQ","LU2265009873.SGD","USJW.SI",".IXIC","LU0648001328.SGD","LU1508157978.USD","TSYW.SI","LU1917777945.USD","LU2237443622.USD","MNQmain","LVS","IE00BFXG1179.USD","AIG","LU0918141705.HKD","LU2106854487.HKD","LU2237443549.SGD","SG9999014005.SGD","SLE","LU2249611893.SGD","LU2065169927.USD","CSGP","IE00B19Z9Z06.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1577},{"period":"3month","weight":0.1614},{"period":"6month","weight":0.6432},{"period":"1year","weight":0.5168},{"period":"ytd","weight":-0.1473}],"compareEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":0.011},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1185},{"period":"1year","weight":0.1504},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.019577},{"month":2,"riseRate":0.777778,"avgChangeRate":0.080513},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.037813},{"month":4,"riseRate":0.555556,"avgChangeRate":0.008622},{"month":5,"riseRate":0.333333,"avgChangeRate":0.130548},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032539},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction